Latest News

Deal of the Year (£10m to £50m) - Shore Capital acted as Financial and Rule 3 Adviser to Styles & Wood Group plc

READ MORE

Life Science Analysis: RNA therapeutics are now a clinical reality

READ MORE

Shore Capital acted as Nominated Adviser & Sole Bookrunner on the IPO of Nucleus Financial Group

READ MORE
SEE ALL NEWS

Message from the Executive Chairman

Featured Service

Research

Within our sector coverage Shore Capital follows industries and stocks from top to bottom. In this respect, we are distinctive in offering competitive and well established analysis in FTSE-100 stocks right down to AIM and FTSE Small-Cap equities.

LEARN MORE